By Chris Wack
Codexis shares were 20% higher, at $3.07, after the company recorded its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis Innovation Lab.
The Redwood City, Calif., company on Monday also said it has successfully completed development of the first generation of its core ECO Synthesis enzymes, having met the pre-specified criteria to support scaling to industrial capacity.
Codexis provides enzymatic solutions for therapeutics manufacturing, developing high-performance enzymes to be used for small-molecule pharmaceuticals manufacturing and nucleic-acid synthesis.
The stock hit its 52-week low of $2.43 on Friday, and is down about 11% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 24, 2025 10:57 ET (14:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.